Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients

doi:10.1111/1759-7714.14046

HFCAS OpenIR

	Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients
	Gong, Lei 1,2; He, Ronghui 3; Xu, Yanjun 1,2; Luo, Taobo 2,4; Jin, Kaixiu 3; Yuan, Wuzhou 5; Zheng, Zengguang 2,6; Liu, Lanxuan 3; Liang, Zebin 3; Li, Ao 5; Zheng, Zhiguo 2,7; Li, Hui 1,2
	2021-06-15
发表期刊	THORACIC CANCER
ISSN	1759-7706
通讯作者	Zheng, Zhiguo(zhengzg@zjcc.org.cn) ; Li, Hui(11118029@zju.edu.cn)
摘要	Background The prognosis for patients with stage II/III non-small cell lung cancer (NSCLC) is unsatisfactory, even after complete tumor resection and adjuvant chemotherapy. Here, we assessed the prognostic and predictive value of immunogenomic signatures for stage II/III NSCLC in Chinese patients. Methods A total of 91 paired resected stage II/III NSCLC and normal tissues, including 47 squamous cell lung carcinomas (SCC) and 44 lung adenocarcinomas (ADC), were collected and analyzed using whole exome sequencing (WES) to identify immunogenomic signatures for association with clinicopathological variables and disease-free survival (DFS). Results Higher neoantigen load (NAL, >2 neoantigens/Mb) exhibited better DFS for SCC patients (p = 0.021) but not ADC patients. A benefit from adjuvant chemotherapy was correlated with lower NAL (<= 2 neoantigens/Mb) (p = 0.009). However, tumor mutation burden (TMB), mutations of individual gene, oncogene pathways, and antigen presentation machinery genes, and human leukocyte antigen (HLA)-I number and HLA-I loss of heterozygosity (LOH) had no prognostic or predictive value for DFS of SCC or ADC patients. Conclusions NAL is a useful biomarker for lung SCC prognosis and prediction of chemotherapy responses in Chinese patients. The predictive value of NAL for adjuvant immunotherapy should be further explored in patients with resected NSCLC.
关键词	biomarker neoantigen load NSCLC prognosis whole exome sequencing
DOI	10.1111/1759-7714.14046
关键词[WOS]	TUMOR ; BURDEN
收录类别	SCI
语种	英语
资助项目	Natural Science Foundation of Zhejiang Province[LQ21H160004] ; Zhejiang Medical technology program[202143913]
项目资助者	Natural Science Foundation of Zhejiang Province ; Zhejiang Medical technology program
WOS研究方向	Oncology ; Respiratory System
WOS类目	Oncology ; Respiratory System
WOS记录号	WOS:000661389300001
出版者	WILEY
引用统计	被引频次：6[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/123773
专题	中国科学院合肥物质科学研究院
通讯作者	Zheng, Zhiguo; Li, Hui
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou 310022, Peoples R China 2.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Peoples R China 3.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China 5.Mingma Technol Co Ltd, Shanghai, Peoples R China 6.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Zhejiang Canc Res Inst, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Gong, Lei,He, Ronghui,Xu, Yanjun,et al. Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients[J]. THORACIC CANCER,2021.
APA	Gong, Lei.,He, Ronghui.,Xu, Yanjun.,Luo, Taobo.,Jin, Kaixiu.,...&Li, Hui.(2021).Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients.THORACIC CANCER.
MLA	Gong, Lei,et al."Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients".THORACIC CANCER (2021).